Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087021 | 1.00 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21087308 | 1.00 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21118015 | 1.00 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21087030 | 1.00 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21117967 | 1.00 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21087400 | 1.00 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21087023 | 0.97 | DGAT1 (0.54) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21117940 | 0.91 | DGAT1 (0.55) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21087205 | 0.91 | DGAT1 (0.51) | DGAT1FOLH1MMP2MMP9MMP8 | |
| SCHEMBL21118069 | 0.90 | DGAT1 (0.56) | DGAT1FOLH1MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | GIPR, GLP1R, GCGR | DGAT1 315/4885FOLH1 320/4885MMP2 3067/4885 |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | IAPP, GLP1R, GIPR | DGAT1 581/4885FOLH1 175/4885MMP2 1455/4885 |
| US-11058775-B2 | Insulin dimer-incretin conjugates | IAPP, GLP1R, GIPR | DGAT1 581/4885FOLH1 175/4885MMP2 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.